Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.4MCash on Hand
13.7mo Cash Runway
Follow SLBT by emailGet an email when SLBT reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about SLBT, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 3, 2026 ·
Leadership Dr. Ethan Shen resigned as director and Chief Technology Officer effective November 1, 2026, not due to any disagreement with the Company. The Board appointed Dr. Chin-Sheng Hung as director and Chief Medical Officer effective the same date. Form 6-K · SEC filing
Oct 26, 2026 ·
Earnings SL Science reported H1 2026 revenue of $1,386,608 and a net loss of $2,162,205, versus a $1,602,089 loss a year earlier. Cash and equivalents rose to $8,306,692 after a $7,800,000 PIPE unit issuance tied to a June 12, 2026 recapitalization. Amount due to a director was $1,600,000. Form 6-K · SEC filing · Press release
Sep 24, 2026 ·
Listing Under Nasdaq's home country practice exemption, the company will not follow certain Nasdaq governance rules, including board independence, annual shareholder meetings, proxy solicitation and shareholder approval of certain dilutive issuances. Cayman counsel Ogier confirmed the practice is permitted under Cayman law. Form 6-K · SEC filing · Press release
Sep 1, 2026 ·
Leadership Vice President of Finance Johnson Lau resigned on August 24, 2026, effective August 31, 2026. The board accepted the resignation, which was not due to any disagreement with the Company. Form 6-K · SEC filing
Aug 27, 2026 ·
Leadership Replaced auditor: appointed TAAD LLP on August 21, 2026, after dismissing ARK Pro CPA & Co on August 20, 2026. The company says the change was not due to any disagreement with ARK. ARK's prior report on the company included a going-concern explanatory paragraph. Form 6-K · SEC filing
Aug 14, 2026 ·
Financing Prospectus for resale of up to 1,040,000 ordinary shares by selling shareholders, following the June 12, 2026 closing of the Business Combination with Horizon Space Acquisition II Corp. The company receives no proceeds. Shares last traded at $2.67 on Nasdaq on August 12, 2026. Form 424B3 · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
💰 Cash Runway & Dilution Risk
SLBT holds $3.4M in cash and short-term investments and burns about $738,541/quarter from operations,
an estimated runway of 13.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:41 · Elevated
Cash runway 14 months +18
S-1 registration (Jul 2026) +8
Going-concern doubt in the latest 20-F +15These conditions raise substantial doubt about its ability to continue as a going concern.20-F, Jun 2026
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SLBT and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.